Supplementary Figures 1-10 from FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1
Dmitri Pchejetski(University of East Anglia), Olivier Cuvillier(Centre National de la Recherche Scientifique), Bernard Malavaud(Université Toulouse III - Paul Sabatier), Justin Teissié(Centre National de la Recherche Scientifique), Vishal A. Salunkhe(Lund University), N. Doumerc(Hôpital Rangueil), Torsten Böhler(Charité - Universitätsmedizin Berlin), Lysann Sauer(Centre National de la Recherche Scientifique), Leyre Brizuela(Centre National de la Recherche Scientifique), Jonathan Waxman, Muriel Golzio(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
Recommendations guidelines on the key information to be reported in studies of application of PEF technology in food and biotechnological processes
|Innovative Food Science & Emerging Technologies|2016|296
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity
|Nature Communications|2016|287
Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models
|Cancer Research|2005|203
Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis
|Circulation Research|2006|197
The emerging role of FTY720 (Fingolimod) in cancer treatment
|Oncotarget|2016|174